JP2019515025A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515025A5
JP2019515025A5 JP2019502543A JP2019502543A JP2019515025A5 JP 2019515025 A5 JP2019515025 A5 JP 2019515025A5 JP 2019502543 A JP2019502543 A JP 2019502543A JP 2019502543 A JP2019502543 A JP 2019502543A JP 2019515025 A5 JP2019515025 A5 JP 2019515025A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
optionally substituted
membered monocyclic
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019502543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/025779 external-priority patent/WO2017176648A1/en
Publication of JP2019515025A publication Critical patent/JP2019515025A/ja
Publication of JP2019515025A5 publication Critical patent/JP2019515025A5/ja
Pending legal-status Critical Current

Links

JP2019502543A 2016-04-04 2017-04-03 トポイソメラーゼ毒 Pending JP2019515025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662318139P 2016-04-04 2016-04-04
US62/318,139 2016-04-04
PCT/US2017/025779 WO2017176648A1 (en) 2016-04-04 2017-04-03 Topoisomerase poisons

Publications (2)

Publication Number Publication Date
JP2019515025A JP2019515025A (ja) 2019-06-06
JP2019515025A5 true JP2019515025A5 (cg-RX-API-DMAC7.html) 2020-05-14

Family

ID=60000629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019502543A Pending JP2019515025A (ja) 2016-04-04 2017-04-03 トポイソメラーゼ毒

Country Status (6)

Country Link
US (1) US11091498B2 (cg-RX-API-DMAC7.html)
EP (1) EP3442979A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019515025A (cg-RX-API-DMAC7.html)
CN (1) CN109219610A (cg-RX-API-DMAC7.html)
CA (1) CA3019945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017176648A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824771B (zh) * 2019-03-07 2020-06-30 中国药科大学 一种降糖肽及其应用
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981731A (en) 1961-04-25 Acridine derivatives
US2985661A (en) 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
US2915523A (en) 1956-12-03 1959-12-01 Parke Davis & Co Benzacridine compounds
US3272707A (en) 1964-07-17 1966-09-13 Smith Kline French Lab Pharmaceutical compositions and methods for their use
CH420045A (de) 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien
US3267107A (en) 1964-09-17 1966-08-16 American Home Prod 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines
US3849561A (en) 1964-10-20 1974-11-19 S Naruto Anti-peptic ulcer substance from corydalis tubers
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3542782A (en) 1967-03-15 1970-11-24 Sandoz Ag 5,6-dihydro-8h-isoquino(1,2-b)quinazolines
JPS4942700A (cg-RX-API-DMAC7.html) 1972-08-25 1974-04-22
US3912740A (en) 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
PT73763B (fr) 1981-10-01 1983-10-26 Quatrum Empresa Nacional De Qu Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
US5153178A (en) 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
IE55519B1 (en) 1982-05-14 1990-10-10 Maroko Peter R Use of a protoberberine alkaloid and composition containing same
US4749708A (en) 1982-05-14 1988-06-07 Maroko Peter R Composition for improving circulatory performance
US4980344A (en) 1982-05-14 1990-12-25 Maroko Peter R Compositions for improving circulatory performance
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS61130289A (ja) 1984-11-29 1986-06-18 Ss Pharmaceut Co Ltd 13−プロピルベルベリンの塩
FR2595356B1 (fr) 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
SU1530628A1 (ru) 1987-11-20 1989-12-23 Ленинградский Технологический Институт Им.Ленсовета Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
DE69430752T2 (de) 1993-09-28 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Tetracyclische verbindungen
US5807874A (en) 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
CA2221248A1 (en) 1995-05-17 1996-11-21 Leroy Fong Liu Tribenzimidazoles useful as topoisomerase i inhibitors
US5767142A (en) 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
PL328402A1 (en) 1996-02-12 1999-01-18 Rutgers Analoques of coralline as inhibitors of topoisomerase
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
BR9711296A (pt) 1996-09-23 1999-08-17 Univ Rutgers Composto processo terap-utico para inibir o crescimento de c-lulas de c ncer e composi-Æo farmac-utica
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
WO2000021537A1 (en) 1998-10-14 2000-04-20 Purdue Research Foundation Novel indenoisoquinolines as antineoplastic agents
WO2001032631A2 (en) 1999-10-29 2001-05-10 Rutgers, The State University Of New Jerey Heterocyclic cytotoxic agents
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
CA2467279A1 (en) 2001-11-14 2003-06-26 Edmond J. Lavoie Solubilized topoisomerase poison agents
DE60225943T2 (de) 2001-11-14 2009-01-29 Rutgers, The State University Topoisomerase-giftmittel
ATE405568T1 (de) 2001-11-14 2008-09-15 Univ Rutgers Cytotoxische mittel
AU2002363658B2 (en) 2001-11-14 2008-09-11 Rutgers, The State University Solubilized topoisomerase poisons
US6989387B2 (en) 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents
AU2003268075A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
AU2003290818A1 (en) 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2006065448A2 (en) 2004-11-18 2006-06-22 Threshold Pharmaceuticals, Inc. Topoisomerase inhibitors and prodrugs
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
JP2010519310A (ja) * 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
PE20090245A1 (es) * 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
JP5773888B2 (ja) 2009-03-06 2015-09-02 ラットガーズ,ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ[i]フェナントリジン誘導体
WO2010127363A1 (en) * 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
CN104822656B (zh) * 2012-05-15 2018-05-01 西雅图基因公司 自稳定接头偶联物
US9580511B2 (en) 2013-03-11 2017-02-28 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering

Similar Documents

Publication Publication Date Title
JP2016515561A5 (cg-RX-API-DMAC7.html)
CY1122761T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
RU2015147447A (ru) Производные доластатина 10 и ауристатинов
JP2016508130A5 (cg-RX-API-DMAC7.html)
JP2017509586A5 (cg-RX-API-DMAC7.html)
JP2018507877A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2017526677A5 (cg-RX-API-DMAC7.html)
JP2016516043A5 (cg-RX-API-DMAC7.html)
JP2014511891A5 (cg-RX-API-DMAC7.html)
JP2018516917A5 (cg-RX-API-DMAC7.html)
JP2015520769A5 (cg-RX-API-DMAC7.html)
CY1122226T1 (el) Προφαρμακα που περiλαμβανουν συζευγμα εξενδινης αρθρωτη
JP2016530259A5 (cg-RX-API-DMAC7.html)
JP2016513696A5 (cg-RX-API-DMAC7.html)
JP2017502994A5 (cg-RX-API-DMAC7.html)
JP2009536620A5 (cg-RX-API-DMAC7.html)
JP2015024998A5 (cg-RX-API-DMAC7.html)
JP2015521195A5 (cg-RX-API-DMAC7.html)
JP2015527318A5 (cg-RX-API-DMAC7.html)
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
JP2014508804A5 (cg-RX-API-DMAC7.html)
JP2019500387A5 (cg-RX-API-DMAC7.html)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
JP2016537382A5 (cg-RX-API-DMAC7.html)